# iMMagine-3 (NCT06413498)

> A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06413498
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Kite, A Gilead Company
- Conditions: Multiple Myeloma
- Interventions: Anitocabtagene Autoleucel; Cyclophosphamide; Fludarabine; Pomalidomide; Bortezomib; Dexamethasone; Daratumumab; Carfilzomib
- Enrollment: 452
- Primary outcome: Progression-Free Survival (PFS)
- Primary outcome: Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 26
- YouTube: 13
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=immagine-3-nct06413498

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06413498", "email": "<work email>"}; the inbox owner confirms by the emailed link.